Voya Investment Management LLC Purchases 145,890 Shares of Glaukos Co. (NYSE:GKOS)

Voya Investment Management LLC increased its holdings in Glaukos Co. (NYSE:GKOS - Free Report) by 266.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 200,698 shares of the medical instruments supplier's stock after buying an additional 145,890 shares during the period. Voya Investment Management LLC owned 0.36% of Glaukos worth $30,093,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in the stock. William Blair Investment Management LLC acquired a new position in Glaukos in the 4th quarter valued at $121,390,000. Alliancebernstein L.P. lifted its position in Glaukos by 1,235.4% during the fourth quarter. Alliancebernstein L.P. now owns 816,153 shares of the medical instruments supplier's stock worth $122,374,000 after purchasing an additional 755,035 shares during the period. Norges Bank bought a new stake in Glaukos during the fourth quarter worth about $84,490,000. Raymond James Financial Inc. acquired a new stake in Glaukos during the fourth quarter worth about $16,910,000. Finally, Vanguard Group Inc. raised its position in shares of Glaukos by 1.7% in the 4th quarter. Vanguard Group Inc. now owns 5,974,971 shares of the medical instruments supplier's stock valued at $895,887,000 after buying an additional 101,838 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors.

Insider Transactions at Glaukos

In other news, insider Tomas Navratil sold 3,416 shares of the business's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the sale, the insider now owns 72,437 shares of the company's stock, valued at $10,658,380.18. The trade was a 4.50 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Alex R. Thurman sold 1,520 shares of the business's stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total transaction of $162,396.80. Following the sale, the chief financial officer now directly owns 53,431 shares in the company, valued at $5,708,568.04. The trade was a 2.77 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 6.40% of the company's stock.

Glaukos Trading Down 0.2 %

Shares of GKOS stock traded down $0.20 on Tuesday, hitting $93.61. The company had a trading volume of 914,995 shares, compared to its average volume of 648,426. Glaukos Co. has a twelve month low of $77.91 and a twelve month high of $163.71. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. The firm has a market cap of $5.34 billion, a P/E ratio of -32.62 and a beta of 0.88. The stock's 50-day moving average is $99.73 and its two-hundred day moving average is $129.65.

Glaukos (NYSE:GKOS - Get Free Report) last issued its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.02). Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The business had revenue of $105.50 million during the quarter, compared to the consensus estimate of $100.72 million. On average, equities research analysts anticipate that Glaukos Co. will post -1.08 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on GKOS shares. Wells Fargo & Company increased their price target on shares of Glaukos from $153.00 to $160.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. Needham & Company LLC lifted their price target on Glaukos from $149.00 to $176.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Stifel Nicolaus upped their price objective on Glaukos from $153.00 to $175.00 and gave the stock a "buy" rating in a research report on Tuesday, December 31st. Piper Sandler decreased their target price on Glaukos from $180.00 to $165.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 15th. Finally, Mizuho dropped their target price on shares of Glaukos from $200.00 to $175.00 and set an "outperform" rating for the company in a report on Wednesday, April 16th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $156.17.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.